OSacc

OSacc performs gene expression-based survival analysis in adrenocortical carcinoma by integrating transcriptomic profiles with clinical follow-up to assess the prognostic significance of genes.

Key Features:

• Data Integration: Integrates seven independent transcriptomic profiles encompassing clinical follow-up of 259 adrenocortical carcinoma (ACC) patients from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO).
• Survival Analysis Capabilities: Generates Kaplan-Meier (KM) survival plots and computes hazard ratios (HR) and log-rank tests to evaluate the prognostic impact of individual genes.
• Prognostic Biomarker Evaluation: Correlates gene expression with clinical outcomes to support identification, evaluation, and validation of prognostic biomarkers.

Scientific Applications:

• Biomarker Discovery: Identification of candidate prognostic biomarkers whose expression correlates with patient survival in ACC.
• Clinical Research: Validation of existing prognostic markers and assessment of novel gene markers in ACC cohorts.
• Translational Research: Linking genomic expression findings to clinical outcome analyses to inform potential translational strategies in ACC.

Methodology:

Integration of seven transcriptomic datasets from TCGA and GEO for 259 ACC patients and application of Kaplan-Meier survival analysis with hazard ratios and log-rank tests.